NIKI logo

NIKI BIOSOLUTIONS INC

NIKINASDAQ
🏆 #5145 by market capUS Equity
$4.76▲ $0.06 (+1.28%)
Live
🔔
Track NIKI
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.3%
7d▼ 4.8%
14d▼ 24.0%
30d▼ 43.0%
ytd▼ 59.3%
1y▼ 73.8%
🏦Market Cap
$17M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
7.1%
Thin
💵FCF Margin
—
⚖️P/S Ratio
4.8x
Fair
Otter Score
56
Weak

Trading Snapshot

Day Range
$4.71 – $4.78
52-Week Range
$4.52 – $12.24
Volume
$2.55B
Avg Volume
$2.99B
Shares Outstanding
3.6M
Next Earnings
Dec 3, 2026

Fundamentals Snapshot

Annual Revenue
$1M
Last Q Revenue
$285,377
P/E Ratio
—
P/S Ratio
4.8x
EPS (TTM)
$-3.54
Dividend Yield
—
Dilution (1yr)
+16.9%

Why Investors Own NIKI

  • ✓High-growth profile — revenue up +24.2% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 25% gross margin and 21% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

NIKI logo

NIKI BIOSOLUTIONS INC

NIKI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
2.4%▼ −60.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$2M▼ −52.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$2M▲ +54.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
74K▲ +16.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$10K▲ +$2M YoY
StockOtter · stockotter.space

About NIKI BIOSOLUTIONS INC

Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences. The company focuses on developing and commercializing a diverse portfolio of therapeutic and diagnostic assets. Its work spans from treatments for diseases with unmet medical needs, particularly in oncology and infectious diseases, to the development of innovative, blood-based diagnostic tests for brain health and other conditions.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$4.95
▲ +4.1% Upside
High Target$5.95
Low Target$4.43
Based on 13 analysts

Latest News & Updates

GlobeNewsWire·4d ago

Niki BioSolutions to Participate in the Lytham Partners Fall 2026 Investor Conference

NEW HAVEN, CT and PRINCETON, NJ, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Niki BioSolutions, Inc. (NASDAQ: NIKI), a life sciences company focused on addressing unmet medical needs and providing high-quality genomic and biomark

GlobeNewsWire·15d ago

Niki BioSolutions Accelerates Its Alzheimer's Disease Testing Pipeline Through Strategic Bioinformatics and Statistical Analysis Partnership with Fios Genomics

Advanced multi-omics data analysis and biostatistical expertise to sharpen target and biomarker decisions across the platform

GlobeNewsWire·21d ago

Niki BioSolutions to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

Live company presentation will take place on September 14 at 10:30 AM ET NEW HAVEN, CT and PRINCETON, NJ, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Niki BioSolutions, Inc. (NASDAQ: NIKI), a life sciences company focused on addr